BRAIN Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

BRAIN Biotech şirketinin toplam hissedar öz sermayesi €17.6M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €74.1M ve €56.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€12.97m
Eşitlik	€17.56m
Toplam yükümlülükler	€56.59m
Toplam varlıklar	€74.15m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0RFI 'nin kısa vadeli varlıkları ( €30.6M ) kısa vadeli yükümlülüklerini ( €11.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0RFI 'un kısa vadeli varlıkları ( €30.6M ) uzun vadeli yükümlülüklerini ( €44.7M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0RFI borçsuzdur.

Borcun Azaltılması: 0RFI un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0RFI şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 0RFI serbest nakit akışı her yıl % { 5.5 2.3 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

BRAIN Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: €0.12 loss per share (vs €0.084 loss in 3Q 2023)

BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025

BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025

Now 25% undervalued

BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025

Forecast breakeven date pushed back to 2026

Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)

BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024

Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022)

BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024

New minor risk - Market cap size

Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022)

BRAIN Biotech AG to Report Fiscal Year 2023 Results on Jan 17, 2024

BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited.

No longer forecast to breakeven

First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023

BRAIN Biotech AG Announces Executive Changes

BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023

Forecast to breakeven in 2025

La Cultura Verde Ltd. acquired LA Schmitt from BRAIN Biotech AG (XTRA:BNN).

No longer forecast to breakeven

No longer forecast to breakeven

Brain Biotech Ag Announces Resignation of Bernhard Hauer from Supervisory Board, as of May 31, 2022

Brain Biotech AG Announces Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas, BRAIN-Engineered-Cas

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Forecast to breakeven in 2024

Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020)

BRAIN Biotech AG (XTRA:BNN) acquired additional 16.7% stake in Biocatalysts Limited from two minority shareholders for £3.9 million.

BRAIN Biotech AG Successfully Completes the First Development Phase for A Novel Genome Editing Tool Based on A Non-Cas9 Nuclease

First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020)

B.R.A.I.N. Biotechnology Research and Information Network AG to Report First Half, 2021 Results on May 28, 2021

Revenue misses expectations

Revenue misses expectations

Full year 2020 earnings released: €0.52 loss per share

Roquette, BRAIN AG, and Brain Group Company AnalytiCon Discovery Successfully Completes the R&D Phase for the Development of Brazzein

B.R.A.I.N. Biotechnology Research and Information Network AG (XTRA:BNN) acquired Biosun Biochemicals Inc.

B.R.A.I.N. Biotechnology Research and Information Network Ag Announces Appointments in Supervisory Board

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin